Skip to main content
Caplight Logo









SeraNovo

SeraNovo

Private
LeidenHealthcare & Life Scienceshttps://seranovo.com

Momentum

Top 50%

of companies Caplight tracks

Company Overview

SeraNovo operates in Healthcare & Life Sciences and is based in Leiden. It was founded in 2017.

SeraNovo is a pharmaceutical formulation company that specializes in improving the oral bioavailability of active pharmaceutical ingredients using its proprietary NanoGlass™ technology platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Non-AI

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

SeraNovo Comparables

Compare SeraNovo with similar companies based on industry and business-model similarity.

SeraNovo comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Nanoform Finland Oyj
76%
Crystal Pharmatech
74%
Catalent
65%
Book a demo to see all comparables

For institutional investors. Book with your work email.

SeraNovo Funding Rounds

Historical fundraising activity

Funding history

No completed funding rounds are published for SeraNovo. Book a demo to ask about coverage.

Book a demo

For institutional investors. Book with your work email.

Key People

Founding team and executive leadership

Ian Degeling

Co-Founder & Chief Technology Officer

Founding Team

Niall Hodgins

Co-Founder and CEO

Founding Team

For institutional investors. Book with your work email.

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 26, 2026

    Monthly visitors increased 44% MoM, reaching 2K.

  • Feb 21, 2026

    Grew 50% QoQ, from 10 to 15 employees.

Book a demo to see all signals

For institutional investors. Book with your work email.

SeraNovo Filings

Explore SEC and related filing metadata, where available.

SeraNovo filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about SeraNovo's valuation, stock price, and market status.

Is SeraNovo a public or private company?

SeraNovo is a private company.

What is the current stock price of SeraNovo?

SeraNovo is a private company, so its shares have no public market price. Caplight tracks SeraNovo's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is SeraNovo worth (valuation)?

Valuation information for SeraNovo is not publicly available.

Can I buy SeraNovo stock?

SeraNovo shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was SeraNovo's last funding round?

Funding round information for SeraNovo is not publicly available.

Who are the main investors in SeraNovo?

Investor information for SeraNovo is not publicly disclosed.

Will SeraNovo IPO soon?

No public IPO plans have been announced for SeraNovo.

How can I track SeraNovo secondary market activity?

Caplight tracks bids, offers, and trades in SeraNovo's shares on secondary markets.

Firmographic Details

HeadquartersLeiden
Employee Range12
Year Founded2017
Last Funding—

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?